Search

Purpose: The purpose of this article is to examine the feasibility of broadly implementing teal management within businesses. Through a critical review of existing literature, the authors express skepticism towards the widespread adoption of this management style in typical business settings. However, the article also delves into an engaging case study, highlighting a specific social organization where the application of teal management demonstrates more promising outcomes. The research findings indicate that teal management may be more effectively employed in social organizations, where its principles align more closely with organizational needs and culture. Ultimately, the article aims to present these research results and the derived conclusions, offering a nuanced perspective on the applicability of teal management across different types of organizations. Findings: In the course of this work, it was found that the principles of teal management can be fully implemented in practice, especially within social organizations such as foundations and associations. This is because these organizations are driven by the passion and commitment of their members, aligning well with the core principles of teal management. Conversely, the application of teal management in business enterprises is more limited due to inherent conflicts over resources, power, and remuneration, which are not in alignment with the teal organization's ideals. Although some aspects of teal management are gradually being adopted in business settings, the full implementation remains challenging at the current level of human consciousness and organizational development. Originality/Value: This paper provides new insights into the practical application of teal management principles, particularly within social organizations. It highlights the unique alignment between the goals of social organizations and the ideals of teal management, offering a nuanced understanding of why these principles may be less applicable in business settings. This work is valuable for organizational leaders, management theorists, and policymakers interested in innovative management practices and organizational development. [ABSTRACT FROM AUTHOR]

As predation by grass snakes was the most common cause of mortality in this study, the inference to be drawn is that the yellow-bellied toad's aposematic coloration is not sufficient defense against these snakes. Telemetric research reveals predation on the poisonous yellow-bellied toad Bombina variegata The most common predator of adult yellow-bellied toads turned out to be the grass snake I Natrix natrix i (Figure 1c), which devoured toads with transmitters attached to them. The reason for the extremely limited data on the predation of adult yellow-bellied toads may lie in the difficulties of actually observing predation in the wild. [Extracted from the article]

Since the start of the Russian Invasion of Ukraine on 24.02.2022, millions of people (mostly women and children) have fled Ukraine. Majority of them fled to Poland and providing adequate medical care for the massive influx of refugees is a considerable challenge for the Polish healthcare system, already burdened by the COVID-19 pandemic and staff shortages. The purpose of this study was to identify: the potential health problems of the incoming population, the legal and ethical aspects of the refugee crisis and its implications on public health. Combining the current data with previous research on refugee crises reveals a set of issues that need to be addressed. Ensuring continuity of chronic disease treatment, mental health, the risk of spreading vaccinable preventable diseases, high rates of tuberculosis, HIV and the ongoing COVID-19 pandemic are among the main concerns. In the near future, answers will have to be found to the emerging ethical questions of equal, safe access to care, implications of the language barrier, immunisation coverage, medical staff shortages, and existing legal and ethical regulations. As the emergency responses are addressed, the hosting countries need to prepare long-term resolutions. [ABSTRACT FROM AUTHOR]

Copyright of Pain Research / Ból is the property of Index Copernicus International and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The discontinuation of futile therapy is increasingly discussed in Polish clinical practice. Given the need to ensure patient well-being, it is essential to consider whether all clinical options resulting from medical progress should be used for every patient and on what grounds decisions to limit therapy should be based. The aim of our study was to determine the opinions of Polish medical doctors on this topic. We anonymously surveyed physicians across various specialties. An analysis of the collected data was carried out using descriptive and analytical methods. A total of 323 physicians participated in the study; 93% of them were aware of the problem of futile therapy in adults, with intensivists being significantly more aware (P = 0.002). Additionally, 95% of respondents supported the idea of discontinuing futile therapy, and over 68% used the therapy discontinuation protocol. Among the most common reasons for undertaking futile therapy, respondents cited fear of legal liability (93.5%), as well as fear of being accused of unethical behavior (62.2%) and fear before talking to the patient/patient's family and their reactions (57.9%). Respondents also identified factors that would facilitate making decisions about limiting futile therapy, including precise qualification criteria for limiting therapy and education in this area (95.3%), the patient's declaration of will (87.5%), and a clear legal act (81.3%). The majority of study participants supported the idea of limiting futile therapy, and this issue is well known among Polish physicians., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Public Health Association.)

Aims: Renin-angiotensin-aldosterone system inhibitors (RAASi) are foundational in the management of heart failure (HF) and chronic kidney disease (CKD) but increase the risk of hyperkalaemia. To facilitate continuation of RAASi therapy, guidelines suggest managing hyperkalaemia using newer potassium binders such as sodium zirconium cyclosilicate (SZC). This observational study describes the likelihood of continued RAASi therapy by duration of SZC treatment., Methods: The study population included non-dialysis-dependent adults diagnosed with HF and/or CKD who initiated outpatient SZC treatment while receiving RAASi therapy. Patients were identified using healthcare registers and claims data from the United States, Japan and Spain. SZC treatment duration was described using the Kaplan-Meier method. Hernán's clone-censor-weight (CCW) approach, using principles of trial emulation, was applied to evaluate the likelihood of continued RAASi therapy at specific time points by distinct SZC treatment durations, using a weighted Kaplan-Meier method and Z-tests., Results: The study included 7980 patients, from the United States (n = 4849), Japan (n = 2759) and Spain (n = 372). Across the three countries, mean patient age was 73.1-75.0 years, 53.2%-66.4% of patients were male, 39.0%-75.0% had HF and 76.9%-95.3% had CKD. Between Days 30 and 120, the percentage of patients remaining on SZC treatment decreased from 36.5% to 12.8% in the United States, from 63.8% to 33.7% in Japan, and from 81.9% to 65.0% in Spain. In the United States, patients who continued SZC treatment beyond 30 days had a higher likelihood of continuing RAASi therapy for up to 90 days (P < 0.001), and continuing SZC treatment beyond 60 days was superior for continuing RAASi therapy for up to 6 months (P < 0.001), versus earlier SZC discontinuation. At 120 days, the likelihood of remaining on RAASi therapy was 69%-70% for SZC treatment durations exceeding 60 days, versus 59% for shorter durations (1-30 days) (P < 0.001). Similar patterns were observed in Japan. At 120 days, the likelihood of remaining on RAASi therapy was 86%-87% for SZC treatment durations exceeding 90 days, versus 82% for shorter SZC treatment durations (1-30 days) (P < 0.05). The CCW analyses were not deemed feasible in the Spanish dataset due to the smaller initial sample size and few patients having a relatively short SZC treatment duration., Conclusions: Patients with longer SZC treatment experience sustained protection against RAASi discontinuation, and the risk of RAASi discontinuation resumes once SZC is discontinued., (© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)